Tempus AI's main products and services are divided into advanced diagnostic testing and data-driven analytical solutions. Its diagnostic portfolio includes specialized genomic sequencing assays, hereditary cancer panels, and molecular testing kits utilized by physicians to personalize oncology treatments. Additionally, the company offers data licensing platforms, artificial intelligence modeling tools, and clinical trial matching software designed to help pharmaceutical researchers discover new therapies and optimize clinical workflows.
Periodic public disclosures regarding congressional stock transactions track investments made by prominent lawmakers and their spouses.
Determining whether Tempus AI is undervalued depends on how investors weigh its high growth rates against its premium valuation multiples.
Determining whether to invest in Tempus AI depends entirely on an individual investor's portfolio strategy, risk tolerance, and perspective on artificial intelligence applications in healthcare.
The largest blocks of Tempus AI stock are held collectively by prominent institutional investment firms, large asset management complexes, and early-stage venture capital backers.
Tempus AI is tracking toward full-year profitability metrics for fiscal year 2026, supported by robust revenue guidance scaling between 1.595 billion and 1.
Tempus AI maintains a balanced capital structure featuring various financing instruments, including convertible senior notes and operating lease commitments, with total liabilities running close to 1.9 billion US dollars.
Institutional investors, major asset management firms, venture capital funds, and technology-focused conglomerates actively invest in Tempus AI.
Tempus AI, Inc. (trading under the Nasdaq ticker symbol TEM) is a technology-driven healthcare enterprise that leverages artificial intelligence and machine learning to advance precision medicine.
For the full fiscal year 2026, Tempus AI expects robust financial performance, having raised its revenue guidance to a range between 1.595 billion and 1.605 billion US dollars, representing approximately 25% annual growth.
Official congressional stock trading disclosures and public transaction registries do not indicate any direct personal or spousal acquisition of Tempus AI shares by Nancy Pelosi.
Tempus AI priced its initial public offering at 37.00 US dollars per share when it debuted on the Nasdaq Global Select Market under the ticker symbol TEM.
Providing a definitive stock price prediction for Tempus AI (NASDAQ: TEM) looking out toward the year 2030 is fundamentally speculative, as multi-year equity forecasts are subject to extreme volatility, evolving macroeconomic climates, and shifting h...
Predicting the precise peak or future upward trajectory of Tempus AI stock is impossible, as equity prices fluctuate based on unpredictable market dynamics, quarterly financial earnings, and macroeconomic conditions.
Determining whether Tempus AI represents a favorable purchase or sale depends entirely on an individual investor's portfolio strategy, risk tolerance, and perspective on artificial intelligence applications in healthcare.
Tempus AI operates at the intersection of healthcare, artificial intelligence, and precision medicine, competing with a range of specialized health-tech, genomics, and data analytics firms.
Tempus AI is transitioning toward sustained profitability, recently posting positive quarterly GAAP net income and growing Adjusted EBITDA figures alongside robust double-digit top-line revenue expansion.
Tempus AI has achieved notable operational milestones in its transition toward sustained profitability, recently reporting positive GAAP net income and growing Adjusted EBITDA figures alongside robust double-digit top-line revenue expansion.
Official congressional stock trading disclosures and public financial transparency records do not indicate any direct personal or spousal investments in Tempus AI shares by Nancy Pelosi.
Tempus AI is recognized as a major and rapidly scaling enterprise within the healthcare technology and precision medicine sectors, commanding a market capitalization of several billion US dollars.
Tempus AI generates revenue primarily through two core segments: Diagnostics and Data & Applications.
Downward price adjustments or pullbacks in Tempus AI stock are typically driven by broader market rotations away from unprofitable high-growth technology equities, shifting investor sentiment toward healthcare sector valuations, or quarterly earnings...
Shares of Tempus AI (NASDAQ: TEM) are held by a diverse cross-section of institutional investment firms, large mutual fund complexes, venture capital backers, corporate insiders, and individual public retail shareholders.
Tempus AI is uniquely distinguished by its ability to bridge clinical medicine and artificial intelligence through one of the world's largest repositories of multimodal clinical and molecular data.
Tempus AI maintains its primary corporate headquarters and central executive offices in Chicago, Illinois, within the United States.
Elon Musk's primary artificial intelligence venture is xAI, an advanced enterprise he founded to develop cutting-edge frontier models, including the generative AI assistant Grok.